382 related articles for article (PubMed ID: 31394352)
1. The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study.
Mitelpunkt A; Kramer U; Hausman Kedem M; Zilbershot Fink E; Orbach R; Chernuha V; Fattal-Valevski A; Deutsch L; Heffetz D; Sacks H
Epilepsy Behav; 2019 Sep; 98(Pt A):233-237. PubMed ID: 31394352
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
[TBL] [Abstract][Full Text] [Related]
3. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
Sands TT; Rahdari S; Oldham MS; Caminha Nunes E; Tilton N; Cilio MR
CNS Drugs; 2019 Jan; 33(1):47-60. PubMed ID: 30460546
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy.
Wheless JW; Dlugos D; Miller I; Oh DA; Parikh N; Phillips S; Renfroe JB; Roberts CM; Saeed I; Sparagana SP; Yu J; Cilio MR;
CNS Drugs; 2019 Jun; 33(6):593-604. PubMed ID: 31049885
[TBL] [Abstract][Full Text] [Related]
7. Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy.
Pietrafusa N; Ferretti A; Trivisano M; de Palma L; Calabrese C; Carfì Pavia G; Tondo I; Cappelletti S; Vigevano F; Specchio N
Paediatr Drugs; 2019 Aug; 21(4):283-290. PubMed ID: 31179531
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of oral cannabis extracts in children with epilepsy.
Knupp KG; Rice JD; Helmkamp LJ; Galinkin J; Sempio C; Jost K; Chapman KE
Seizure; 2019 Nov; 72():23-27. PubMed ID: 31550641
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.
Szaflarski JP; Bebin EM; Comi AM; Patel AD; Joshi C; Checketts D; Beal JC; Laux LC; De Boer LM; Wong MH; Lopez M; Devinsky O; Lyons PD; Zentil PP; Wechsler R;
Epilepsia; 2018 Aug; 59(8):1540-1548. PubMed ID: 29998598
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience.
Chen KA; Farrar M; Cardamone M; Gill D; Smith R; Cowell CT; Truong L; Lawson JA
Med J Aust; 2018 Aug; 209(5):217-221. PubMed ID: 30092753
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.
Gaston TE; Ampah SB; Martina Bebin E; Grayson LP; Cutter GR; Hernando K; Szaflarski JP;
Epilepsy Behav; 2021 Apr; 117():107862. PubMed ID: 33667843
[TBL] [Abstract][Full Text] [Related]
13. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
[TBL] [Abstract][Full Text] [Related]
14. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial.
Scheffer IE; Hulihan J; Messenheimer J; Ali S; Keenan N; Griesser J; Gutterman DL; Sebree T; Sadleir LG
JAMA Netw Open; 2021 Sep; 4(9):e2123930. PubMed ID: 34477852
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Porcari GS; Fu C; Doll ED; Carter EG; Carson RP
Epilepsy Behav; 2018 Mar; 80():240-246. PubMed ID: 29429908
[TBL] [Abstract][Full Text] [Related]
16. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.
Gaston TE; Bebin EM; Cutter GR; Ampah SB; Liu Y; Grayson LP; Szaflarski JP;
Epilepsy Behav; 2019 Sep; 98(Pt A):201-206. PubMed ID: 31382177
[TBL] [Abstract][Full Text] [Related]
17. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.
Patel S; Grinspoon R; Fleming B; Skirvin LA; Wade C; Wolper E; Bruno PL; Thiele EA
Epilepsia; 2021 Jul; 62(7):1594-1603. PubMed ID: 34050682
[TBL] [Abstract][Full Text] [Related]
18. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
19. Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study.
Klotz KA; Grob D; Schönberger J; Nakamura L; Metternich B; Schulze-Bonhage A; Jacobs J
CNS Drugs; 2021 Nov; 35(11):1207-1215. PubMed ID: 34687005
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.
Szaflarski JP; Bebin EM; Cutter G; DeWolfe J; Dure LS; Gaston TE; Kankirawatana P; Liu Y; Singh R; Standaert DG; Thomas AE; Ver Hoef LW;
Epilepsy Behav; 2018 Oct; 87():131-136. PubMed ID: 30100226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
